Verastem Oncology is ending an early-stage trial of its MEK inhibitor Avmapki in lung cancer and pivoting to another program that it says could have a greater impact on patients.
The biotech
Read More from Endpoints News
Verastem axes Phase 1/2 lung cancer trial of Avmapki, pivots to KRAS blocker
